CMAB vs IMAB in Metastatic Prostate Cancer

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bicalutamide; Goserelin

Criteria

Inclusion Criteria:

• Histological diagnosis of D2 of Adenocarcinoma,

• Naivety to treatment

• Valuable bone metastasis

Exclusion Criteria:

• Hematological, liver or renal toxicity Grade IV

• Severe and active infections